Innovation Pharmaceuticals Inc (IPIX)

[williamssc]

My opinion if Brilacidin meets it's potential as a broad-spectrum antiviral it may likely win approval in this current climate. We have strong reported evidence so far of B's anti-viral capabilities. The nasal application as an early treatment looks to be a good fit. We wait and see.

“Brilacidin, a Host Defense Peptide Mimetic, is a Broad-Spectrum Countermeasure Strategy Against Acutely Infectious Viruses.”

Across multiple cell lines and under different testing conditions, research showed Brilacidin inhibited viral replication in a statistically significant manner in encephalitic alphaviruses, including Venezuelan Equine Encephalitis Virus (VEEV), Eastern Equine Encephalitis Virus (EEEV), and Sindbis Virus (SINV). Brilacidin also was shown to inhibit Rift Valley Fever Virus (RVRF), a contagious bunyavirus that can lead to blindness, liver failure, and hemorrhagic fever in infected individuals. Moreover, anti-inflammatory activity was observed, indicating intracellular events are modulated by Brilacidin treatment. Brilacidin is thus able to exert a combined protective effect by decreasing viral and inflammatory load.